Hillsboro

Researchers are evaluating the real-world clinical impact of the Galleri4, a blood-based multi-cancer early detection MCED test, in a Medicare population aged 50 years and older. This multi-center prospective cohort study aims to assess the tests safety and performance alongside usual care, enrolling participants representative of Medicare beneficiaries. The study is observational and compares outcomes between those receiving the Galleri test plus usual care and those receiving usual care alone. Participants in the Galleri-tested arm will have blood collected for the MCED test with results returned to guide further evaluation. The comparator group consists of Medicare beneficiaries receiving usual care without the Galleri test. Both groups will be observed over a period of up to 3 years to evaluate cancer incidence and diagnostic outcomes. Throughout the study, researchers will monitor the incidence of stage IV cancers, the number and types of invasive procedures following test results, adherence to recommended cancer screening, and healthcare resource use related to cancer diagnostics. Safety and test performance will be tracked in the Galleri-tested group. Participation involves routine clinical visits and data collection for up to 3 years, with no interventions withheld for either group.

This research aims to find out if a therapist training program can help providers in early childhood settings use powered mobility devices with young children who have cerebral palsy classified at Gross Motor Function Classification System Levels IV-V. The study also evaluates whether the training is practical and helpful for therapists, families, and children, addressing gaps in access to powered mobility during a critical developmental period between 12 and 36 months. The study involves therapists receiving one to two days of in-person training on powered mobility implementation, followed by delivering a six-month intervention to child-caregiver pairs. Therapists conduct twelve biweekly home-based sessions using the Permobil Explorer Mini device, focusing on mobility opportunities, caregiver coaching, and integrating powered mobility into daily routines. The project includes surveys, interviews, and observations to understand barriers, co-design training, and test feasibility. Participants will complete assessments such as surveys, interviews, and video-recorded sessions to evaluate therapist knowledge, confidence, intervention fidelity, and caregiver feasibility of device use. Child outcomes like mobility, participation, and engagement are measured through caregiver reports and standardized assessments. The study spans from training through intervention and includes monitoring of acceptability, appropriateness, and feasibility over the six-month period.

Researchers are evaluating how a conversation tool helps patients with lung cancer make treatment decisions. This study focuses on improving patient-centered health and decision-making outcomes, especially for patients with lower health literacy. The goal is to understand what information patients need to participate effectively in shared decision-making about their lung cancer treatment options. Participants are randomly assigned to one of two groups. One group reviews a decision aid designed to support their treatment choices, while the other group receives the standard care. After the intervention, patients are followed up at 2 weeks, 3 months, and 6 months to assess the effects of the conversation tool. During the study, researchers collect data on patient knowledge about lung cancer, decision conflict, satisfaction with communication, confidence in decision-making, and self-efficacy. Additional outcomes include quality of communication, anxiety and depression levels, participation in decision-making, decision regret, and referrals to palliative care. Questionnaires and some recorded clinic conversations are used to gather information over the 6-month follow-up period.

Researchers are evaluating a new medicine called PF-08634404 combined with chemotherapy for adults with colorectal cancer that has spread to other parts of the body. The study aims to understand how well this new combination works compared to an existing treatment using Bevacizumab with chemotherapy. The study is a phase 3, double-blind, randomized trial focusing on treatment effectiveness and safety in participants who have not received prior systemic therapy for metastatic disease. Participants are randomly assigned to one of two groups. One group receives PF-08634404 with chemotherapy, and the other group receives Bevacizumab with chemotherapy. Both treatments are given through intravenous IV infusions in cycles. Treatment continues as long as it helps and side effects are manageable. Treatments are administered at clinical sites by trained staff. Participants will have regular visits for treatment, health evaluations, and various tests. After stopping treatment, there is a follow-up visit about 30 to 37 days later to review health and side effects. Further follow-up occurs every 12 weeks by phone, in person, or via health record review to monitor health status and any new treatments. The study duration for each participant is approximately 33 months. Researchers will measure progression-free survival, overall survival, response rates, quality of life, and monitor safety throughout the study.